Simulation technologies and animal free testing for rare diseases/precision medicine
There is an urgent need for alternative methodologies to minimize animal and human testing. Not only is the drug development process lengthy and costly, there are a range of issues at stake in addition to safety, efficacy and the related ethical considerations. Furthermore, there is still room for improvement of the prediction of human risks, drug repositioning or re-use. Setting standards for in-silico trials will contribute to the development of new biomedical products.
Knowing that the variability among individuals is high regarding e.g. molecular pathways, cellular microenvironments, genetics, comorbidities gender, behavior, lifestyle and environmental conditions, in-silico trials require large multidisciplinary efforts.